Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy and pharmacogenomic programs.

Syma Iqbal1, Heinz Josef Lenz

  • 1Division of Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.

Cancer
|April 4, 2003
PubMed
Summary

Predicting chemotherapy response and toxicity is crucial. Tumor profiling, including genetic markers, shows promise for personalizing treatments with fluoropyrimidines and platinums, guiding future clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

The Lancet. Oncology·2025
Same author

Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.

Nature communications·2025
Same author

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).

Future oncology (London, England)·2025
Same author

Theranostic Near-Infrared Monoamine Oxidase Inhibitor (NMI) Protein Binding Interactions with MAOA and Albumin.

Pharmaceutical research·2025
Same author

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Area of Science:

  • Oncology
  • Pharmacogenomics

Background:

  • Chemotherapy aims to predict patient response and treatment toxicity.
  • Tumor profiling technologies measure protein expression, gene expression, and genetic polymorphisms.
  • These markers can predict patient response to specific chemotherapeutics.

Purpose of the Study:

  • To explore the potential of tumor profiling in predicting chemotherapy outcomes.
  • To identify specific chemotherapeutics, like fluoropyrimidines and platinums, where marker-based prediction is feasible.

Main Methods:

  • Utilizing advanced technology for comprehensive tumor profiling.
  • Measuring protein expression, gene expression levels, and genetic polymorphisms.
  • Correlating molecular profiles with patient response and toxicity data.

Related Experiment Videos

Main Results:

  • Established markers can predict treatment outcomes for fluoropyrimidines and platinums.
  • Tumor profiling demonstrates potential for personalized chemotherapy selection.

Conclusions:

  • Prospective clinical trials are necessary to validate the benefits of tumor profiling.
  • Personalized profiling is expected to improve chemotherapy response rates and reduce toxicity.